New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
11:31 EDTSAN, GNC, INVN, INO, SD, OREX, UBNT, CREE, WTW, AEGROptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN
News For INO;AEGR;UBNT;INVN;WTW;OREX;GNC;CREE;SD;SAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2015
12:18 EDTGNCCarlson Capital reports 5.34% stake in Vitamin Shoppe, says plans more talks
Subscribe for More Information
11:25 EDTCREEStocks with call strike movement; TWTR CREE
Twitter (TWTR) September 60 call option implied volatility increased 3% to 42, Cree (CREE) August 37.5 call option implied volatility decreased 11% to 34 according to IVolatility.
10:53 EDTCREEOptions with decreasing implied volatility
Subscribe for More Information
09:22 EDTCREEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
19:06 EDTCREEOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTCREECree slides after results
In the extended session shares are currently down more than 5% to $33.54. At that price next support is at $32.73. Resistance is at $34.58.
16:05 EDTCREECree sees Q4 EPS 24c-28c, consensus 29c
Subscribe for More Information
16:02 EDTCREECree reports Q3 adjusted EPS 22c, consensus 23c
Subscribe for More Information
15:28 EDTCREENotable companies reporting after market close
Subscribe for More Information
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link
13:58 EDTCREEEarnings Watch: Cree to report Q3 results as LED sector gains momentum
Subscribe for More Information
08:29 EDTUBNTUbiquiti Networks results likely to beat expectations, says Bernstein
Subscribe for More Information
05:33 EDTINOInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
April 20, 2015
07:22 EDTSDIndependent Petroleum Association of America to hold a conference
IPAA-OGIS New York is being held in New York on April 20-22.
April 17, 2015
10:39 EDTCREECree April weekly volatility elevated at 126 into Q1 and outlook
Cree April weekly call option implied volatility is at 86, May is at 56, June is at 41, September at 36; compared to its 26-week average of 37 according to Track Data, suggesting larger near term price movement into the expected release of Q1 results on April 21.
April 15, 2015
06:41 EDTSANECB authorizes new emergency funding for Greek banks, Reuters reports
Subscribe for More Information
06:33 EDTSDSandRidge Energy coverage resumed with a Sell at Goldman
Subscribe for More Information
April 14, 2015
10:01 EDTINVNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:22 EDTINVNInvenSense upgraded to Buy from Neutral at Rosenblatt
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use